The share price of Conba Pharmaceutical’s soared today after the Chinese firm announced it has planted its first crop of industrial hemp. Conba Pharma’s [SHA:600572] share price rose by the daily limit of 10 percent to CNY6.60...
Read moreGilead Sciences and Nurix, based in Forest City, Calif. and San Francisco, respectively, signed a global strategic collaboration deal that could hit $2.48 billion. The focus will be on discovering drugs that use the body’s natural protein control...
Read moreCellular Biomedicine, a New York-Shanghai company, has started a China Phase I trial of its CD20 CAR-T candidate in patients who relapsed after CD19 treatment. The patients have either relapsed diffuse large B-cell lymphoma or small B-cell...
Read moreCARsgen Therapeutics, a Shanghai CAR-T company, was approved to start US trials of its fully human BCMA (B-Cell Maturation Antigen)-CAR-T therapy for patients with relapsed/refractory multiple myeloma. Four months ago, China’s NMPA approved...
Read moreIntrexon Corporation (Intrexon) (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve quality of life and health of the planet, and Surterra Wellness (Surterra), one of the fastest growing health and wellness...
Read moreBeiGene Co.,Ltd (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks...
Read moreCASI Pharma, a US-China company, obtained global rights to an autologous anti-CD19 T-cell therapy developed by Juventas Cell Therapy of Tianjin City, China. Juventas has filed China INDs to test CNCT19 as a treatment for two leukemia and lymphoma...
Read moreHutchison China MediTech (Chi-Med) will stop its Phase III trial of surufatinib early following positive interim data showing the candidate met its primary endpoint of progression-free survival. The China trial was testing surufatinib in patients...
Read moreSuzhou Innovent Biologics reported that its fully-human BCMA CAR-T candidate produced a 100% objective response rate in patients with relapsed/refractory multiple myeloma (RRMM). CT103A was co-developed by Innovent and Nanjing IASO...
Read moreNeptune Wellness Solutions Inc. (“Neptune” or the “Company”) (NASDAQ:NEPT) (TSX:NEPT) is pleased to announce that its wholly owned subsidiary, 9354-7537 Québec Inc., has received a notification letter from Health Canada...
Read moreProposed acquisition strengthens Pfizer’s innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term Opportunity to strengthen category leadership in Oncology with the addition of...
Read moreJiangsu Hengrui Medicine in-licensed greater China rights to a treatment for chronic yeast infections from Mycovia Pharma of Durham, North Carolina. Mycovia is currently conducting a Phase III trial of VT-1161 (otesaconazole) in women with...
Read more
